EX-10.1.4



 Exhibit 10.1.4 

AMENDMENT NO. 4 TO THE PATENT LICENSE AGREEMENT NO. C-00061901 

BETWEEN: 
 L’Institut Pasteur, a public
interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Christophe Mauriet, Adjunct General Manager, 
 Hereafter referred to as
“IP” or the “LICENSOR”, acting both on its own behalf and on behalf of: 
  

	•	 	Université Pierre et Marie Curie, 4, place de Jussieu, 75252 Paris Cedex 05, hereafter referred to as “UPMC”, 

  

	•	 	Institut Curie, 26, rue d’Ulm, 75248 Paris cedex 05, hereafter referred to as “IC”, 

  

	•	 	Le Centre National de la Recherche Scientifique, 3, rue Michel-Ange, 75794 Paris Cedex 16, hereafter referred to as “CNRS”. 


Jointly also referred to as the “LICENSOR”, 
 Party
of the first part, 
 AND: 
 CELLECTIS, a
public limited company with a capital of 1,023,803.15 euros, headquartered at 8 Rue de la Croix Jarry, 75013 Paris cedex 15, represented by Mr. André Choulika, acting as Chief Executive Officer 

Hereafter referred to as “Cellectis” or the “Licensee”, 

Party of the second part. 
 The LICENSOR and LICENSEE are
hereafter referred to as the “Parties”. 
 RECITALS: 

On June 19, 2000, the Parties signed the license agreement no. C-00061901, modified by amendment no. 1 on March 15, 2001, amendment 2 on
September 8, 2003, amendment 3 on February 26, 2008, (hereafter the “AGREEMENT”) by which the LICENSOR grants the LICENSEE operating rights over certain patent families. 

Following discussions and exchanges between the Parties, they have decided by mutual agreement to remove from the AGREEMENT the patent family based on
priority application FR95/09587 filed on August 7, 1995 and awarded on October 10, 1997, titled “Insertion gene cellule eucaryote”. 

The Parties agree by this Amendment no. 4 to modify Schedule A of the AGREEMENT and the definition of the “AGREEMENT PATENTS” stated in Article 1.2
of the AGREEMENT. 







 It is thus agreed as follows: 

ARTICLE 1 
 The Parties agree that Schedule A of
this Amendment no. 4 replaces Schedule A of the AGREEMENT. 
 The Parties agree that in this Amendment no. 4, French patent no. 9509587, awarded on
October 10, 1997, is excluded from the definition of the “AGREEMENT PATENTS” stated in article 1.2 of the AGREEMENT. 
 The AGREEMENT PATENTS
are hereby defined as follows: 
  

	•	 	U.S. patent application Serial No. 07/879,689 filed on May 5, 1992 in the names of IP and UPMC, titled “Nucleotide sequence encoding the enzyme I-SceI and the uses thereof”, American patent no.
5830729 awarded on November 3, 1998, any divisional applications, “continuing” applications or reissue applications made on the basis of the patents and patent applications cited above, including the PCT extension of this application,
published under no. WO 96 14 408, and patents and patent applications that may result from them, which are listed in Schedule A of this AGREEMENT, and the corresponding awarded patents which will be automatically added to SCHEDULE A of this
AGREEMENT. 

  

	•	 	U.S. patent application Serial No. 634,192 filed on April 18, 1996 in the names of IP, IC and CNRS, which has never been extended abroad, and which gave rise to US patent no. 5 830 729 awarded on
November 3, 1998, any divisional applications, “continuing” applications or re-issue applications filed on the basis of the patent application cited above, and 


 

	•	 	U.S. patent application no. US 275,638 filed on March 15, 2001 and titled “characterization of the I-SpomI Endonuclease from fission yeast”, including the PCT extension of this application, published
under no. WO 02/074965, the patents and patent applications resulting from it, any patent application claiming priority over one of the aforementioned applications, any divisional applications, “continuing” applications or re-issue
applications filed on the basis of the patents and patent applications cited above. 

 ARTICLE 2 

2.1 All other provisions of the AGREEMENT shall remain unchanged and fully applicable between the Parties. 

2.2 This Amendment no. 4 enters into force on its date of signature by the Parties. 

2.3 This Amendment no. 4 and its Schedule form an integral part of the AGREEMENT. 
  

					
	Signed in Paris on		[Handwritten text: April 11, 2103]
	In 2 original copies.		

  

			
	CELLECTIS		INSTITUT PASTEUR








 SCHEDULE A 

AGREEMENT PATENTS 
  

																			
	 Country
	 	 Title
	  	 Filing

Number
	  	 Filing date
	  	 Type
	  	 Holder 1
	  	 Holder 2
	  	 Holder 3
	  	 Issuance
number
	  	 Date

										
	CANADA	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	CA2283569	  	Nov. 6, 95	  		  	Institut Pasteur	  	Université P.M. CURIE	  	CNRS	  		  	
										
	EUROPE	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	EP959384181	  	Nov. 6, 1995	  		  	Institut Pasteur	  	Université P.M. CURIE	  	CNRS	  		  	
										
	JAPON	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	JP51505896	  	Nov. 6, 1995	  		  	Institut Pasteur	  	Université P.M. CURIE	  	CNRS	  		  	
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US971160	  	Nov. 5, 1992	  	Continuation in part	  	Institut Pasteur	  	Université P.M. CURIE	  	CNRS	  	5474896	  	Dec. 12, 95
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US336241	  	Nov. 7, 1994	  	Continuation in part	  	Institut Pasteur	  	Université P.M. CURIE	  		  	5792632	  	Nov. 8, 1998
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US417226	  	April 5, 1995	  	Division	  	Institut Pasteur	  	Université P.M. CURIE	  		  	5962327	  	Oct. 5, 1999









																			
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US465273	  	June 5, 1995	  	Continuation	  	Institut Pasteur	  	Université P.M. CURIE	  		  	5866361	  	Feb 2, 1999
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US461624	  	June 5, 1995	  	Continuation	  	Institut Pasteur	  	Université P.M. CURIE	  		  		  	
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US643732	  	June 5, 1996	  	Continuation in part	  	Institut Pasteur	  	Université P.M. CURIE	  		  		  	
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US119024	  	July 20, 1998	  		  	Institut Pasteur	  	Université P.M. CURIE	  		  	5948678	  	Sept. 7, 1999
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US196131	  	Nov. 20, 1998	  	Continuation	  	Institut Pasteur	  	Université P.M. CURIE	  		  		  	
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US244130	  	Feb. 4, 1999	  	Division	  	Institut Pasteur	  	Université P.M. CURIE	  		  		  	
										
	United States	 	SYNTHETIC GENE CODING FOR I-SceI ENZYME...	  	US492697	  	Jan. 27, 2000	  	Continuation	  	Institut Pasteur	  	Université P.M. CURIE	  	                	  		  	









																			
	 Country
	 	 Title
	  	 Filing

Number
	  	 Filing date
	  	 Type
	  	 Holder 1
	  	 Holder 2
	  	 Holder 3
	  	 Issuance
number
	  	 Date

										
	United states	 	TRANSGENIC ANIMAL HOMOLOGOUS RECOMBINATION	  	US693948	  	Aug. 7, 96	  	Continuation	  	CNRS	  	Institut Pasteur	  	Institut Curie	  	5830729	  	Nov. 3, 98
										
	United states	 	TRANSGENIC ANIMAL HOMOLOGOUS RECOMBINATION	  	US116834	  	July 17, 98	  	Continuation	  	CNR	  	Institut Pasteur	  	Institut Curie	  		  	

 U.S. patent application no. US 275,638 filed on March 15, 2001 and titled “Characterization of the I-SpomI
Endonuclease from fission yeast”, including the PCT extension of this application, published under no. WO 02/ 074965, the patent applications and patents resulting therefrom, any patent applications claiming priority over one of the
aforementioned applications, any divisional applications, any continuing applications or any applications for re-issue filed on the basis of the aforementioned patents and patent applications.